At a glance:
Granules India’s Q4 FY25 results show a classic pharma plot twist — flat revenue, soaring profit. With ₹11,974 Mn revenue (+2% YoY), ₹1,520 Mn PAT (+17% YoY), and a strong EBITDA margin of 21%, the company has managed to out-formulate the odds despite USFDA woes at Gagillapur. For FY25, net profit rose 24% to ₹5,015 Mn. Is the worst behind? Or are we in Act II of the compliance drama?
🏢 About the Company
Granules India Ltd is a vertically integrated pharmaceutical company based in Hyderabad. They operate across the full pharma spectrum — APIs, PFIs, FDs, and now CDMO for peptides — supplying to 300+ customers in 80+ countries with 11 facilities globally (8 India, 2 USA, 1 Switzerland).
Think of them as the 4-in-1 shampoo of Indian pharma. Except, they don’t clean your hair — they clean your liver, gut, and whatever else is ailing.
👨💼 Key Managerial Personnel (KMP)
- Dr. Krishna Prasad Chigurupati – Chairman & MD (aka The Formulator-in-Chief)
- Chaitanya Tummala – Company Secretary & Compliance Whisperer
📊
